REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform. The company's lead product candidate is RGX-314 for the treatment of wet age-related macular degeneration. It is also developing RGX-501 for the treatment of homozygous familial hypercholesterolemia, which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; and RGX-111 to treat the neurological symptoms of Mucopolysaccharidosis Type I that uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system (CNS). In addition, the company engages in the development of RGX-121 for the treatment of neurological symptoms of Mucopolysaccharidosis Type II, which uses the AAV9 vector to deliver the human iduronate-2-sulfatase gene to the CNS. Further, it licenses its NAV technology platform to other biotechnology companies. The company was formerly known as REGENX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RGNX
CUSIPN/A
Phone240-552-8181
Debt
Debt-to-Equity RatioN/A
Current Ratio17.41
Quick Ratio17.40
Price-To-Earnings
Trailing P/E Ratio-26.92
Forward P/E Ratio25.08
P/E Growth8.43
Sales & Book Value
Annual Sales$10.39 million
Price / Sales205.09
Cash FlowN/A
Price / CashN/A
Book Value$5.88 per share
Price / Book11.22
Profitability
EPS (Most Recent Fiscal Year)($2.45)
Net Income$-73,160,000.00
Net Margins44.44%
Return on Equity28.70%
Return on Assets26.89%
Miscellaneous
Employees139
Outstanding Shares32,310,000
Market Cap$2.18 billion
Regenxbio (NASDAQ:RGNX) Frequently Asked Questions
What is Regenxbio's stock symbol?
Regenxbio trades on the NASDAQ under the ticker symbol "RGNX."
How were Regenxbio's earnings last quarter?
Regenxbio Inc (NASDAQ:RGNX) posted its quarterly earnings results on Wednesday, August, 8th. The biotechnology company reported $0.30 earnings per share for the quarter, missing the Zacks' consensus estimate of $1.23 by $0.93. The biotechnology company earned $40.03 million during the quarter, compared to analyst estimates of $100 million. Regenxbio had a return on equity of 28.70% and a net margin of 44.44%. View Regenxbio's Earnings History.
When is Regenxbio's next earnings date?
What price target have analysts set for RGNX?
6 brokers have issued 12-month price targets for Regenxbio's stock. Their forecasts range from $28.00 to $127.50. On average, they anticipate Regenxbio's share price to reach $81.0833 in the next twelve months. This suggests a possible upside of 22.9% from the stock's current price. View Analyst Price Targets for Regenxbio.
What is the consensus analysts' recommendation for Regenxbio?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regenxbio in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Regenxbio.
What are Wall Street analysts saying about Regenxbio stock?
Here are some recent quotes from research analysts about Regenxbio stock:
- 1. Raymond James analysts commented, "We are maintaining our Outperform rating and raising our target price to $76 (previously was $45) for REGENXBIO, primarily driven by our increasing confidence in the company’s pipeline products and the gene therapy space as a whole as well as the inclusion of the company’s wholly owned MPS programs into our models. With two wholly owned assets poised to deliver clinical data in late 2018, a powerful AAV technology platform with >20+ partnered programs (10 of which are in the clinic), and a cash position of $311 million (pro forma), we continue to recommend REGENXBIO shares to risk-tolerant investors." (6/25/2018)
- 2. According to Zacks Investment Research, "REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland. " (4/17/2018)
- 3. Chardan Capital analysts commented, "We have long highlighted the importance of vector science for the progress in GT; and, we see Commissioner Gottlieb’s comments as highly supportive of our views. We again highlight REGENXBIO (Buy) (a Chardan Top Pick for 2017, and our Gene Therapy Top Pick) as the best way to play the emergence of in vivo GT, due to the company’s: (1) rights to 100+ vectors, (2) partnerships with 10 companies, (3) 25 or so internal and external product candidates, over 10 of which are in clinical development, and (4) abundance of important 2017 catalysts, which to us represent upside options." (12/11/2017)
Who are some of Regenxbio's key competitors?
Some companies that are related to Regenxbio include bluebird bio (BLUE), AveXis (AVXS), BIO-TECHNE (TECH), Ablynx (ABLYF), China Biologic Products (CBPO), Aerie Pharmaceuticals (AERI), argenx (ARGX), Halozyme Therapeutics (HALO), Crispr Therapeutics (CRSP), Spark Therapeutics (ONCE), Acceleron Pharma (XLRN), Repligen (RGEN), Momenta Pharmaceuticals (MNTA), Rubius Therapeutics (RUBY) and Atara Biotherapeutics (ATRA).
Who are Regenxbio's key executives?
Regenxbio's management team includes the folowing people:
- Mr. Kenneth T. Mills, CEO, Pres & Director (Age 43)
- Mr. Vittal K. Vasista, Chief Financial Officer (Age 50)
- Dr. Olivier Danos, Chief Scientific Officer (Age 60)
- Mr. Curran M. Simpson, Sr. VP of Technical Operations (Age 56)
- Mr. Patrick J. Christmas II, Sr. VP & Gen. Counsel (Age 47)
Has Regenxbio been receiving favorable news coverage?
News stories about RGNX stock have trended somewhat positive this week, Accern reports. Accern scores the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Regenxbio earned a coverage optimism score of 0.11 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 47.20 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term. View Recent Headlines for Regenxbio.
Who are Regenxbio's major shareholders?
Regenxbio's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (13.21%), RTW Investments LP (6.44%), FMR LLC (5.08%), Redmile Group LLC (4.83%), Bank of New York Mellon Corp (1.00%) and Marshall Wace LLP (0.63%). Company insiders that own Regenxbio stock include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Patrick J Christmas, Stephen Yoo and Vittal Vasista. View Institutional Ownership Trends for Regenxbio.
Which major investors are selling Regenxbio stock?
RGNX stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC, FMR LLC, Vivo Capital LLC, Royce & Associates LP, BlueMountain Capital Management LLC, Altshuler Shaham Ltd, BNP Paribas Arbitrage SA and Cubist Systematic Strategies LLC. Company insiders that have sold Regenxbio company stock in the last year include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Patrick J Christmas, Stephen Yoo and Vittal Vasista. View Insider Buying and Selling for Regenxbio.
Which major investors are buying Regenxbio stock?
RGNX stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Marshall Wace LLP, RTW Investments LP, Voya Investment Management LLC, Bank of New York Mellon Corp, Pier Capital LLC, Acadian Asset Management LLC and Legal & General Group Plc. View Insider Buying and Selling for Regenxbio.
How do I buy shares of Regenxbio?
Shares of RGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Regenxbio's stock price today?
One share of RGNX stock can currently be purchased for approximately $65.95.
How big of a company is Regenxbio?
Regenxbio has a market capitalization of $2.18 billion and generates $10.39 million in revenue each year. The biotechnology company earns $-73,160,000.00 in net income (profit) each year or ($2.45) on an earnings per share basis. Regenxbio employs 139 workers across the globe.
How can I contact Regenxbio?
Regenxbio's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-552-8181 or via email at [email protected]
MarketBeat Community Rating for Regenxbio (NASDAQ RGNX)
MarketBeat's community ratings are surveys of what our community members think about Regenxbio and other stocks. Vote "Outperform" if you believe RGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
